Market Overview:
 
The Chemotherapy-induced Anemia Market size is estimated to reach $4.3 billion by 2030, growing at a CAGR of 7.1% during the forecast period 2024-2030, according to a recent report published by IndustryARC, titled, “Chemotherapy-induced Anemia Market – By Etiology (Cancer Related Anemia, Treatment Related Anemia, Patient Related Anemia), By Treatment Type (RBC Transfusion, Erythropoiesis-stimulating agents (ESAs), Iron Supplementation and Others), By Drug Type (Epogen Injection, Procrit Injection, Androxy Oral, Aranesp Injection, Epoetin Alfa Injection and Others), End User ( Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Cancer Research Centres and Others) and  By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030”
 
The increasing incidence of cancer is driving the market, as more patients undergoing chemotherapy experience related complications like anemia. Additionally, growing awareness of anemia management is prompting healthcare providers and patients to seek effective treatment options, are fueling the growth of the Chemotherapy-induced Anemia industry during the forecast period.
 
North America Dominated the Market in 2023:
 
North America accounted for the largest share of 7.1% of the Chemotherapy-induced Anemia Market in 2023, primarily driven by the region's high prevalence of chronic diseases and cancer. According to the National Library of Medicine, the number of individuals aged 50 and older in the U.S. with at least one chronic condition is projected to rise by 99.5%, increasing from 71.522 million in 2020 to 142.66 million by 2050. This surge in chronic illnesses is closely linked to an aging population that often requires chemotherapy as part of their treatment. Furthermore, a March 2024 report from PubMed forecasts that the U.S. will see 2,001,140 new cancer cases and 611,720 cancer deaths in 2024, with cancer recognized as the second leading cause of death in the country. The increasing number of older adults requiring chemotherapy will inevitably drive the demand for effective anemia treatments, as chemotherapy frequently results in anemia as a side effect. The emphasis on comprehensive care also means that healthcare providers are increasingly focused on managing the quality of life for cancer patients, thereby boosting the demand for effective anemia management solutions. These collectively solidify North America's leading role in the chemotherapy-induced anemia market, suggesting ongoing growth and advancements in the future.
 
Chemotherapy-induced Anemia Market: Key Takeaways
 
Increasing Cancer Incidence
 
As the diagnosis of various cancer types increases, the demand for effective management of chemotherapy-related side effects, such as anemia, continues to rise. According to statistics from the National Cancer Institute in May 2024, it is projected that by 2040, the annual number of new cancer cases will reach 29.9 million, with cancer-related deaths totaling 15.3 million. This surge in cancer cases creates a critical need for innovative therapies that help patients maintain their quality of life throughout treatment. With millions of new cancer diagnoses anticipated in the coming years, healthcare systems are prioritizing the enhancement of support and treatment options for anemia, further driving market growth.
 
For More Queries About "Chemotherapy-induced Anemia Market" @  https://www.industryarc.com/pdfdownload.php?id=509929
 
Growing Awareness of Anemia Management
 
As awareness of anemia's health impacts grows, there is an increasing focus on early detection and effective treatment. Government initiatives and campaigns from healthcare organizations are emphasizing the importance of regular screenings and proactive health measures. For example, in June 2023, India's Prime Minister launched the National Sickle Cell Anemia Elimination Mission 2047 to protect the health and well-being of those affected by the condition. Organizations such as the Anemia Foundation provide resources, webinars, and online support groups to educate patients and caregivers on managing anemia. Health organizations are leveraging social media platforms like Instagram and Twitter to disseminate awareness through infographics, patient stories, and expert interviews, making information about anemia more accessible to a wider audience. This increased awareness is motivating individuals to seek medical advice and undergo testing, resulting in higher diagnosis rates and a growing demand for effective therapies.
 
Scope of the Report: 
 

Report Metric

Details

Base Year Considered

2023

Forecast Period

2024–2030

CAGR

7.1%

Market Size in 2030

$4.3 billion

Segments Covered

By Etiology, By Treatment Type, By Drug Type, By End-User and By Geography.



 

Geographies Covered

North America (U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, , Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), Rest of the World (Middle East and Africa).



 

Key Market Players

1.  Amgen Inc.

2.  Pfizer Inc

3.  3SBIO Inc.

4.  Astellas Pharma Inc.

5.      F. Hoffmann-La Roche Ltd.

6.  FibroGen, Inc.

7.      Ranbaxy Laboratories Ltd.

8.  Bristol-Myers Squibb Company

9.  Johnson & Johnson

10.  Vifor Pharma AG
 
 
Recent Developments:
 
• In September 2023, Akebia Therapeutics, a biotechnology company based in the U.S., received approval from Australia’s Therapeutic Goods Administration (TGA) for Vafseo.
• In August 2023, Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) approved Reblozyl for treating anemia in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who are naive to erythropoiesis-stimulating agents (ESA-naïve) and may require regular red blood cell (RBC) transfusions.
• In February 2023, GlaxoSmithKline Ltd. received approval from the US Food and Drug Administration (FDA) for Jesduvroq (daprodustat). 
Chemotherapy-induced Anemia Market: Competitive Landscape
Key companies profiled in the Chemotherapy-induced Anemia Market are Amgen Inc., Pfizer Inc, 3SBIO Inc., Astellas Pharma Inc., Hoffmann-La Roche Ltd., FibroGen, Inc., Ranbaxy Laboratories Ltd., Bristol-Myers Squibb Company, Johnson & Johnson,Vifor Pharma AG and Others.
 
Related Reports:
 
Chemotherapy-Induced Myelosuppression Treatment Market - Chemotherapy-Induced Myelosuppression Treatment Market size was valued at $14.3 billion in 2020 and is expected to grow with a CAGR of 3.4% during the forecast period 2021-2026 owing to Increasing prevalence of cancer across the globe coupled with rising aging population.
 
Hemoglobinopathies Market -The Hemoglobinopathies Market Size is estimated to reach $14.3 billion by 2027 and it is poised to grow at a CAGR of 10.2% over the forecast period of 2022-2027. Rising clinical trials and activities along with support from critical health authorities are driving the Hemoglobinopathies industry .
 
Single Agent Chemotherapy Market - Single Agent Chemotherapy Market size is estimated to reach $8.2 billion by 2030, growing at a CAGR of 3.9% during the forecast period 2024-2030. The increasing prevalence of cancer globally , government investments and  advances in drug development are propelling the market growth.
 
About IndustryARC™:
 
IndustryARC primarily focuses on Market Research and Consulting Services specific to Cutting Edge Technologies and Newer Application segments of the market. The company’s Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets.  
IndustryARC’s goal is to provide the right information required by the stakeholder at the right point in time, in a format that assists an intelligent and informed decision-making process.
 
Contact Us:
 
Mr. Venkat Reddy
IndustryARC
USA: (+1) 518-282-4727